COVID-19
Conditions
Interventions
Experimental group:Basic treatment + Cangma Huadu granules
Control group:Basic treatment + placebos
Sponsors
Beijing Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Patients who have been diagnosed with mild COVID-19 according to the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial Version 9); (2) 60 years old =aged =18 years old; (3) Treatment time from onset to inclusion =72h; (4) The patient is informed and agrees to sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) Mentally ill persons, or other persons unable to cooperate or unwilling to cooperate; (2) Participants in other trials within the last 3 months; (3) The patient is known to have the following risk factors: a) Pregnant women or women in the puerperal period; b) Chronic respiratory diseases, including COPD and asthma attacks; c) neurological diseases and neurodevelopmental disorders, including brain, spinal cord, peripheral nerve and muscle diseases (e.g., cerebral palsy, epilepsy [convulsive attacks], stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy or spinal cord injury); d) Heart disease (e.g., congenital heart disease, congestive heart failure or coronary artery disease), excluding high blood pressure without any other heart-related symptoms; e) Diseases of the blood system; f) endocrine system diseases (excluding HBA1c < 8%); g) Kidney disease: creatinine clearance =60 mL/min; h) Liver diseases (including hepatitis, cirrhosis, moderate to severe fatty liver, but excluding asymptomatic abnormal liver function with AST or ALT elevated less than 50% of the upper limit of normal); i) Metabolic disorders (protein metabolism, glucose metabolism, lipid metabolism, water and electrolyte metabolism, hyperuricemia); j) compromised immune systems (including patients on immunosuppressive therapy, or patients with cancer or human immunodeficiency virus [HIV] infection); k) Obese patients (body mass index [BMI]=30). (4) Weight of indicator cases < 40 kg; (5) a history of alcohol or drug abuse; (6) have received or are receiving anti-COVID-19 drugs such as Ritonavir and azfudine tablets; (7) Antipyretic and analgesic drugs were used within 6 hours; (8) Chinese patent medicines with antiviral properties (such as Jinhua Qinggan, Lianhua Qingwen, Qingkailing Granules (oral liquid), Shufeng Jiedu capsules, Yinqiao Jiedu, Sangju colds, Yinhuang preparations) should be used within 12h
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptom remission time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to negative of viral nucleic acid;Disease exacerbation rate;Length of stay;Changes of inflammatory and immune indexes before and after treatment; | — |
Countries
China
Contacts
Public ContactQingquan Liu
Beijing Hospital of Traditional Chinese Medicine
Outcome results
None listed